Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06584032
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-21
Brief Title:
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomizedopen-labelmulticenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physicians Choice As Second-line Treatment for Advanced Endometrial Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to evaluate whether fruquintinibHMPL-013 plus sintilimabIBI308 is safe and effective in the treatment of advanced endometrial cancerEMC
Detailed Description:
A randomized open positive-controlled multicenter Phase III clinical study to compare the efficacy and safety of fruquintinibHMPL-013 plus sintilimabIBI308 versus chemotherapy in patients with advanced endometrial cancer who have progressed after first-line standard chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None